RADICAL PROSTATECTOMY AND RADICAL RADIATION-THERAPY FOR CLINICAL STAGE-T1 TO STAGE-T2 ADENOCARCINOMA OF THE PROSTATE - NEW INSIGHTS INTO OUTCOME FROM REPEAT BIOPSY AND PROSTATE-SPECIFIC ANTIGEN FOLLOW-UP
Al. Zietman et al., RADICAL PROSTATECTOMY AND RADICAL RADIATION-THERAPY FOR CLINICAL STAGE-T1 TO STAGE-T2 ADENOCARCINOMA OF THE PROSTATE - NEW INSIGHTS INTO OUTCOME FROM REPEAT BIOPSY AND PROSTATE-SPECIFIC ANTIGEN FOLLOW-UP, The Journal of urology, 152(5), 1994, pp. 1806-1812
Assessment of outcome following radical treatment for stages T1 to T2
prostate cancer has become more sensitive and rapid with the use of se
rum prostate specific antigen (PSA) in routine followup. PSA has ident
ified substantially more failure following all radical therapies than
was previously detected in series using clinical end points. Furthermo
re, it has also allowed a better assessment of the biological potentia
l of histologically evident residual disease, that is a positive surgi
cal margin after prostatectomy or positive repeat biopsy 2 years after
radiation. Both situations are associated with subsequent biochemical
failure in the majority of patients. The stages T1 to T2 cancer group
is extremely heterogeneous. In the few series with PSA followup that
have evaluated long-term (greater than a decade) outcome for this grou
p some report cure rates well below 40% for surgery and radiation. Whe
n comparing the results of any radical treatment series (surgery versu
s surgery and radiation versus radiation, as well as radiation versus
surgery) selection may have a crucial role in predicting outcome. Surg
ical series tend to contain more patients with stages T1 to T2a tumors
of low grade who have low initial PSA values and are known to have ne
gative nodes. These patients, when treated with radical radiation, als
o have a favorable prognosis. It is hoped that the introduction of scr
eening programs will improve outcome through earlier disease detection
.